期刊文献+

取代基物化参数用于2-苯基吲哚衍生物构效关系的研究 被引量:4

QSAR Studies of 2-Phenylindole Derivatives Using Physicochemical Parameters of Substituents
下载PDF
导出
摘要 用取代基电性、立体性和疏水性物化参数对2-苯基吲哚衍生物进行了结构表征,并对化合物与雌激素受体相对亲和力进行定量结构活性相关(QSAR)研究。经逐步回归筛选变量后,所建多元线性回归方程的复相关系数R2及留一法交互检验相关系数R2cv分别为0.900和0.662。用预测集样本进行了外部预测,所得外部预测样本集复相关系数Re2xt和外部预测集交互检验Q2ext分别为0.896 6和0.897 4。模型结果显示:吲哚环1号N原子上立体效应强的取代基有利于亲和力的提高;而吲哚环1号N原子和3号C原子上电性强的取代基、2-苯基环上4′号位置有羟基取代等,均对化合物亲和力的提高不利。 A novel substituent descriptor based on the physicochemical parameters about the electronic, hydrophobic and steric properties of substituents is used to describe the chemical structures of 2- phenylindole derivatives. The variables are reduced using stepwise multiple regression (SMR) method for the training set, and the statistical results indicate that the correlation coefficient square in the multiple linear regression and cross validation using leave one out (LOO) is 0. 900 and 0. 662, respectively. To validate the predictive power of resulting models, external validation are performed with Rext^2 and Qext^2 values of 0. 896 6 and 0.897 4, respectively. The models obtained also shows that the substituents on nitrogen atom of the 1-position of the indole ring have more relative binding affinities. But introduction of substituents with strong electronic effects in 1 and 3 positions of the indole ring and the structure with hydroxy group at in the 4' position of 2-phenyl ring may decrease the binding affinity between the 2-phenylindole derivatives and ligand of estrogen receptor.
出处 《精细化工》 EI CAS CSCD 北大核心 2006年第5期473-477,486,共6页 Fine Chemicals
基金 霍英东基金(98-7-6) 国家春晖计划教育部启动基金(99-1-4/38)~~
关键词 取代基物化参数 2-苯基吲哚衍生物 雌激素受体配体 定量构效关系 physicochemical parameters of substituent 2-phenylindole derivatives ligand of estrogen
  • 相关文献

参考文献21

  • 1Nilsson S, Gustafsson J A. Estrogen receptor transcription and trans - activation basic: aspects of estrogen action [J]. Breast Cancer Res,2000,2(5) :360-366.
  • 2Klinge C M. Estrogen receptor interaction with estrogen response elements [J]. Nucleic Acid Res,2001,29 (4) :2905 - 2919.
  • 3吕秋军,温利青.雌激素受体配体组织选择性作用机制的研究[J].中国药学杂志,2000,35(1):1-3. 被引量:4
  • 4方维,廖清江.选择性雌激素受体调节剂类乳腺癌治疗新药的研究进展[J].药学进展,2004,28(6):247-252. 被引量:5
  • 5Riggs B L, Hartmann L C. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice [J]. N Engt J Med,2003,348(7) :618 -629.
  • 6温险峰,邵志敏,沈镇宙.乳腺癌中ERα和ERβ研究进展[J].国外医学(肿瘤学分册),2001,28(1):60-62. 被引量:11
  • 7Von Angerer E,Prekajac J,Strohmeier J. 2-Phenylindoles ,relationship between structure, estrogen receptor affinity and mammary tumor inhibiting activity in the rat[J]. J Med Chem, 1984,27:1439.
  • 8Von Angerer E,Strohmeier J. 2-Phenylindoles. Effect of N-benzylation on estrogen receptor affinity, estrogenic properties, and mammary tumor [J]. J Med Chem, 1987,30(1):131 - 136.
  • 9Von Angerer E, Knebel N, Kager M,et al. 1 -(Aminoalkyl) -2-phenylindolas as novel pure estrogen antagonists [J]. J Med Chem,1990,33(9) :2635 -2640.
  • 10Mirocha C J, Christensen C M , Nelson G H. Physiologic activity of some fungal estrogens produced by fusarium [J]. Cancer Res,1968 28 (11):2319 - 2322.

二级参考文献74

  • 1杨光富,陈琼,张莉.Phytocassane衍生物的电子结构特征及构效关系研究[J].计算机与应用化学,2002(5):571-574. 被引量:4
  • 2Riggs B L,Hartmann L C.Selective estrogen-receptor modulators--mechanisms of action and application to clinical practice[J].N Engl J Med,2003,348(7):618-629.
  • 3Bouhoute A,Leclercq G E.Derivatives bearing the side-chain of tamoxifen antagonize the association between the estrogen receptor and calmodulin[J].Biochem Pharmacol,1994,47(4):748-751.
  • 4Brzozowski A M,Pike A C W,Dauter Z,et al.Molecular basis of agonism and antagonism in the estrogen receptor[J].Nature (London) ,1997,389(6652): 753-758.
  • 5Shiau A K,Barstad D,Loria P M,et al.The structural basis of oestrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen[J].Cell,1998,95(7): 927-937.
  • 6Miller C P,Collini M D,Tran B D,et al.Design,synthesis,and preclinical characterization of novel,highly selective indole estrogens[J].J Med Chem,2001,44(11): 1654-1657.
  • 7Suh N,Glasebrook A L,Palkowitz A D,et al.Arzoxifene,a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer[J].Cancer Res,2001,61(23): 8412-8415.
  • 8Schafer J M,Liu H,Bentrem D J,et al.Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351[J].Cancer Res,2000,60(18):5097-5105.
  • 9Grese T A,Sluka J P,Bryant H U,et al.Molecular determinants of tissue selectivity in estrogen receptor modulators[J].Proc Natl Acad Sci U S A,1997,94(25):14105-14110.
  • 10Dodge J A,Lugar C W,Cho S,et al.Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity[J].J Steroid Biochem Mol Biol,1997,61(1-2):97-106.

共引文献21

同被引文献31

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部